{"name":"Wang Xin","slug":"wang-xin","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE0yaWdoemxNRFhaYkxLblNKal9kR3IxZ0hDXzJYX3R6c2REZ2ZHb29teHlWS1B6eFZvWW1QaUt4eE5JZFE2alNUSlI1VzM3ajVxazFpZ3JGOGlWRVFra0xJ?oc=5","date":"2026-01-16","type":"pipeline","source":"Nature","summary":"Spatiotemporally controlled drug release via a click-release system utilizing mono-alkyl-hydroxylamine and cyclooctyne chemistry - Nature","headline":"Spatiotemporally controlled drug release via a click-release system utilizing mono-alkyl-hydroxylamine and cyclooctyne c","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE5HZXNoM01RWEc3VVZaMzVuUlB4amh0OVc0WGhvT2k5cUlOdlkzQ21UM0hqbkk2OFR6dVAyeUxMVW8zOHhJR3htektiNVVza1JrUXFJNzdvd3hwdkQ4bW5rdFJsdGdwdUNxQkFoSDBVeTZIamxEZFZJZTdVU0w1Zw?oc=5","date":"2025-05-11","type":"pipeline","source":"Yahoo Finance","summary":"Dr. Yuxin Chen, President and CEO of Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd., Honored as a 2025 Forbes China Pioneer Innovators in Industry Development - Yahoo Finance","headline":"Dr. Yuxin Chen, President and CEO of Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd., Honored as a 2025 Forbe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE8xS2duWXc0aWl4SDNZZlZPbDd3YnVZQUwwS1lyOTNsZDQ5ZUVfT0x3RmZjUDViYjE5aWNRamg5Y3Z0dlJ0Umo5aXE4VFYwR3hPQ1ZzU184RmxxWDJVN0xF?oc=5","date":"2025-01-03","type":"pipeline","source":"Nature","summary":"Radiopharmaceuticals and their applications in medicine | Signal Transduction and Targeted Therapy - Nature","headline":"Radiopharmaceuticals and their applications in medicine | Signal Transduction and Targeted Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTFBoaTlDNjROZHVIemVISXF1NGgyVHJFUy1CLUJ4Zk9hcEZsZXdiUnVhdXJ4bU55VklTVEsxcjlmRlJSZzFJdEVBY0VlWGFZVjM1QW5RY2RfYjFRNHMxSzRDSDh3?oc=5","date":"2024-11-09","type":"pipeline","source":"ACS Publications","summary":"Bioorthogonal Chemistry-Guided Inhalable Nanoprodrug to Circumvent Cisplatin Resistance in Orthotopic Nonsmall Cell Lung Cancer - ACS Publications","headline":"Bioorthogonal Chemistry-Guided Inhalable Nanoprodrug to Circumvent Cisplatin Resistance in Orthotopic Nonsmall Cell Lung","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiT0FVX3lxTFBnVTE3MXlrcG5yaU5Iak9Vamd5WVRwRFVBRjJ1NVM4TFIzUXVyc0YwalVyS1dxNFp4RWNZMXRZU29HRklTc2FYWkwzNzM3RVE?oc=5","date":"2024-11-01","type":"pipeline","source":"Sixth Tone","summary":"AstraZeneca Executive Behind China Growth Under Investigation - Sixth Tone","headline":"AstraZeneca Executive Behind China Growth Under Investigation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE8xUkdyODBOWTNGWjU3c21ZX2lwUnVfUDFkcEIzczlSSWlnaW5VdmhXRUFjRkFrOTZwRDhUTU1aa3lobmNHSFRVRW5IOGJPanFnU1RPVG5XOENVMFdrcFhEZUYxNWNuWHdaNHNjaTRTU0FPbXM?oc=5","date":"2024-10-20","type":"pipeline","source":"British Pharmacological Society | Journals","summary":"Recent strategies in target identification of natural products: Exploring applications in chronic inflammation and beyond - British Pharmacological Society | Journals","headline":"Recent strategies in target identification of natural products: Exploring applications in chronic inflammation and beyon","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOdXV3N3pILUh0b0dwc1ZVQWRNb2ZYVkZ3ejQ0Vnh6ZXcxdExhbE1TZXk2U3N1aGdxT3VadUZkeGFxLUgtcENaUUpvS2NQdWo0Z25QYlhPVWNPV3ZYM2VjdmgwVkN3Y2tjTFJKNUJhVThIaFZ5cWY2ZDRtVGFvQ2FSRE1SM0FmN3RJb2ctQzlNS0c?oc=5","date":"2024-06-14","type":"pipeline","source":"ScienceDirect.com","summary":"Journal of Pharmaceutical Analysis - ScienceDirect.com","headline":"Journal of Pharmaceutical Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTFBqdm9pdFo1MTJHZ3Q5ZHduR2tST3FmZDdBY0dfUThwQzRKWGRmaHlMYnFDZ1BZcE9lSVBvQWxKbU5PTWd4X1Y2ZmJ2dDZpMHB2cl9RX0ZCSnpkZw?oc=5","date":"2022-08-13","type":"pipeline","source":"日本女子プロゴルフ協会","summary":"Xin Wang MEMBERS INFO｜JLPGA｜The Ladies Professional Golfers' Association of Japan - 日本女子プロゴルフ協会","headline":"Xin Wang MEMBERS INFO｜JLPGA｜The Ladies Professional Golfers' Association of Japan - 日本女子プロゴルフ協会","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOVmFIWnFwTEp6VDNfM05zVGFvUkUtckVmdjA0NDJkLTJjUmc3UDB0SlFydFBVbUN0WFlJNENFMTRoMGdBRHdsa2dmN243SkxMOHJwa01JM3lva09NUUxfZTJIY0w4TGFnZG1QT2VBaWtBSE9fNjV4dklDOUI4a2lnNjRlZFB3SGJqYWpYZjIxdTE3OU9JbkVieF9ycHRNQQ?oc=5","date":"2022-02-10","type":"regulatory","source":"drugdiscoverytrends.com","summary":"Chinese regulators approve GSK’s Benlysta for lupus nephritis - drugdiscoverytrends.com","headline":"Chinese regulators approve GSK’s Benlysta for lupus nephritis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE9jajhQaXpyN0lHVDEtTGZkajNhVV9LNDBrLXBHVlVrcXQwSmg5Yjc5OVd1N0I1aFpaUHNjbjJGbVUwY0NmZERTX1FIR3JxUExwUm5JRmJfQVpucEk?oc=5","date":"2021-05-12","type":"pipeline","source":"EurekAlert!","summary":"Acta Pharmaceutica Sinica B Volume 11, Issue 4 publishes - EurekAlert!","headline":"Acta Pharmaceutica Sinica B Volume 11, Issue 4 publishes - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPYnVTcWVrQTcwdG5Pd0RsYXpsM2F2clV1T3duV3d0UnhNcEI4VXVXcmFFN0NpWjBYUGNpNEt6c2w5cXFjWkVlZGlVQy0wWV8xVElWNVFERjluRjV4YVJlTGxfMkFNc0lqWHoxY2VXel96alZ5MFQ0eEhmZEEyNWgtNVNzUVhodFVfV1ZZ?oc=5","date":"2020-10-22","type":"trial","source":"The Lancet","summary":"The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries - The Lancet","headline":"The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE8wd2FvejZ0Yzg4bElvYXZSeDlyTXNiU1ZuR3NNSURCR1JNLUxkNDJ1UzJqUWhvd080NVhERC1hZWNQemd6WURheVlsUVV5RGV6ckVuYWZNUHpRTDFxUUgw?oc=5","date":"2019-07-31","type":"pipeline","source":"NEJM","summary":"Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia - NEJM","headline":"Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}